Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspective
N Kakouros, JJ Rade, A Kourliouros… - International journal of …, 2011 - Wiley Online Library
Patients with diabetes mellitus have an increased prevalence of vascular disease.
Pathologic thrombosis associated with atherosclerotic plaque rupture is a major cause of …
Pathologic thrombosis associated with atherosclerotic plaque rupture is a major cause of …
Medical Therapy for Long-Term Prevention of Atherothrombosis Following an Acute Coronary Syndrome: JACC State-of-the-Art Review
G Gallone, L Baldetti, M Pagnesi, A Latib… - Journal of the American …, 2018 - jacc.org
Following an acute coronary syndrome (ACS), heightened predisposition to
atherothrombotic events may persist for years. Advances in understanding the pathobiology …
atherothrombotic events may persist for years. Advances in understanding the pathobiology …
Randomized comparisons of double-dose clopidogrel or adjunctive cilostazol versus standard dual antiplatelet in patients with high posttreatment platelet reactivity …
YD Tang, W Wang, M Yang, K Zhang, J Chen, S Qiao… - Circulation, 2018 - Am Heart Assoc
Background: Patients undergoing percutaneous coronary intervention react differently to
antiplatelet drugs. Those with low responsiveness to clopidogrel have a higher risk of …
antiplatelet drugs. Those with low responsiveness to clopidogrel have a higher risk of …
Comparative effects of different antiplatelet strategies in carriers of CYP2C19 loss-of-function alleles: a network meta-analysis
M Galli, G Occhipinti, S Benenati… - European Heart …, 2024 - academic.oup.com
Background Carriers of cytochrome 2C19 (CYP2C19) loss-of-function (LoF) alleles treated
with clopidogrel have impaired drug metabolism, resulting in reduced active metabolite …
with clopidogrel have impaired drug metabolism, resulting in reduced active metabolite …
Association of cytochrome P450 2C19* 2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents
Background Although East Asians carry the cytochrome P450 (CYP) 2C19* 2 allele more
frequently than do Caucasians, the impact of the CYP2C19* 2 allele on clopidogrel …
frequently than do Caucasians, the impact of the CYP2C19* 2 allele on clopidogrel …
Clinical efficacy and safety of cilostazol: a critical review of the literature
KC Rogers, CS Oliphant, SW Finks - Drugs, 2015 - Springer
Cilostazol is a unique antiplatelet agent that has been commercially available for over two
decades. As a phosphodiesterase III inhibitor, it reversibly inhibits platelet aggregation yet …
decades. As a phosphodiesterase III inhibitor, it reversibly inhibits platelet aggregation yet …
Effects of genetic variants on platelet reactivity and one-year clinical outcomes after percutaneous coronary intervention: a prospective multicentre registry study
Clopidogrel is the mainstay for antiplatelet treatment after percutaneous coronary
intervention (PCI). The relationship of platelet reactivity and genetic polymorphism with …
intervention (PCI). The relationship of platelet reactivity and genetic polymorphism with …
Role of cytochrome P450 genotype in the steps toward personalized drug therapy
Genetic polymorphism for cytochrome 450 (P450) enzymes leads to interindividual
variability in the plasma concentrations of many drugs. In some cases, P450 genotype …
variability in the plasma concentrations of many drugs. In some cases, P450 genotype …
Genetic determinants of clopidogrel responsiveness in Koreans treated with drug-eluting stents
JJ Park, KW Park, J Kang, KH Jeon, SH Kang… - International journal of …, 2013 - Elsevier
BACKGROUND: Variations of genes encoding cytochrome enzymes, drug transporters, and
paraoxonase have recently been reported to be associated with clopidogrel response …
paraoxonase have recently been reported to be associated with clopidogrel response …
Genetic and non-genetic factors affecting the response to clopidogrel therapy
M Karaźniewicz-Łada, D Danielak… - Expert opinion on …, 2012 - Taylor & Francis
Introduction: Clopidogrel (CLP) is a second-generation thienopyridine that prevents platelet
aggregation by inhibiting the adenosine diphosphate receptor located on the platelet …
aggregation by inhibiting the adenosine diphosphate receptor located on the platelet …